Biotech and Money recently caught up with Mark Denham, Fund Manager and Head of Pan European Equities at Aviva Investors. He joined the firm in 1999 and in his current role deals in equities, using all-cap and growth strategies.

We had the opportunity to learn his thoughts about the latest trends in the market, what drives his decision to invest or not in a healthcare company and crucially where he’s looking for opportunity in this space.

 
Download the interview to learn:

• How Mark and Aviva’s unique approach has led them to consistently beat index benchmarks by between 4-5% per annum
• How Mark assesses healthcare investment opportunities and why Healthcare has such a large weighting in his portfolio
• What Mark believes the industry needs to do to cultivate generalist investor interest and make biotech more appealing
• Mark’s outlook and perspectives on the sector, capital markets, M&A, valuations

DOWNLOAD IT HERE